David Godwin Rabkin

Dr. David Godwin Rabkin


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MJMohan M. John
Mohan M. John
WSWendy Shih
Wendy Shih
DEDennys Estevez
Dennys Estevez
TMTimothy P. Martens
Timothy P. Martens
LBLeonard L. Bailey
Leonard L. Bailey
DRDavid Godwin Rabkin
David Godwin Rabkin

1 May 2019 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
ASAgustin Sibona
Agustin Sibona
KKKiran K. Khush
Kiran K. Khush
UOUdo E. Oyoyo
Udo E. Oyoyo
TMTimothy P. Martens
Timothy P. Martens
NHNahidh W. Hasaniya
Nahidh W. Hasaniya
DRDavid Godwin Rabkin
David Godwin Rabkin

1 March 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DTDavid Tryon
David Tryon
NHNahidh W. Hasaniya
Nahidh W. Hasaniya
BJBrice Jabo
Brice Jabo
ARAnees J. Razzouk
Anees J. Razzouk
LBLeonard L. Bailey
Leonard L. Bailey
DRDavid Godwin Rabkin
David Godwin Rabkin

12 March 2022 in Clinical Transplantation
Verified
Journal Article
Open access
JPJay N. Patel
Jay N. Patel
DADmitry Abramov
Dmitry Abramov
MFMarat Fudim
Marat Fudim
IOIke S. Okwuosa
Ike S. Okwuosa
DRDavid Godwin Rabkin
David Godwin Rabkin
JCJoshua S. Chung
Joshua S. Chung
Background: Patients with blood group O have historically been disadvantaged in the United Network for Organ Sharing (UNOS) heart transplant allocation system. We sought to determine whether the new UNOS allocation system implemented in 2018 had an impact on waitlist and post‐transplant outcomes among blood groups.Methods: Using the UNOS database we included all adult patients listed and transplanted with first‐time single‐organ heart transplant between 10/17/15 and 10/1/21. For post‐transplant outcomes, we separately evaluated all adult patients transplanted with the same time‐frame. We used exclusion criteria and censoring to limit biases from changing clinical practices around the allocation change (10/18/2018), and from unequal or inadequate follow‐up. We compared clinical characteristics and outcomes before and after the allocation change among each blood group. Fine‐Gray and Cox regression models were used to estimate the effect of the new allocation system on competing waitlist outcomes‐ transplantation, death‐or‐removal from waitlist‐ and post‐transplant survival, respectively.Results: Of the 21,565 patients listed for transplantation 14,000 met criteria for waitlist analysis (7,035 in the old system vs. 6,965 in the new), and 7,657 met criteria for post‐transplant analysis (3,519 in the old system vs. 4,138 in the new). Among each blood group, new allocation change was associated with higher transplantation rates lower waitlist days and lower waitlist mortality (except Group AB). However, despite improvements, Group O was still associated with worse waitlist outcomes for each metric compared to non‐O Groups. The new allocation system did not have a significant impact on post‐transplant survival among any blood groups.Conclusion: Changes in heart transplant allocation have attenuated but not eliminated blood group O disadvantage in access to donor hearts.

13 October 2022 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
AMAbdul Mannan Khan Minhas
Abdul Mannan Khan Minhas
DADmitry Abramov
Dmitry Abramov
JCJoshua S. Chung
Joshua S. Chung
JPJay Patel
Jay Patel
MMMamas A. Mamas
Mamas A. Mamas
DRDavid Godwin Rabkin
David Godwin Rabkin
We sought to determine utilization and outcomes of perioperative temporary mechanical circulatory support (tMCS) in the current practice of cardiac surgery. tMCS is an evolving adjunct to cardiac surgery not fully characterized in contemporary practice. Using the nationwide inpatient sample we retrospectively analyzed hospital discharge data between January 1, 2016 and December 31, 2019. ICD‐10‐CM procedure codes were used to identify and divide patient hospitalizations into those who had preoperative tMCS (pre‐tMCS) versus tMCS instituted the day of surgery or afterwards (sd/post‐tMCS). In all, 1,383,520 hospitalizations met inclusion criteria. 86,445 (6.25%) had tMCS. tMCS was utilized in 8.74% of coronary artery bypass grafting (CABG), 2.58% of isolated valve, and 9.71% of valve/CABG; operations. 29,325 (33.9%) had pre‐tMCS while 57,120 (66.1%) had sd/post‐tMCS. The use of tMCS was associated with greater inpatient mortality (15.66% vs. 1.53%, p < .001), longer length of stay (LOS) (14.4 vs. 8.5 days, p < .001), and higher mean inflation‐adjusted costs ($93,040 ± 1038 vs. $51,358 ± 296, p < .001) compared to no use. Inpatient mortality (5.98% vs. 20.63%, p < .001), LOS (13.87 vs. 14.68, p < .001), and cost ($82,621 ± 1152 SEM vs. $98,381 ± 1242) were all significantly lower with pre‐tMCS compared to sd/post tMCS. When analyzed separately, mortality was higher with later utilization of tMCS (5.98% pre, 17.1% sd, and 49.05% postsurgical date insertion, p < .001). Perioperative tMCS is utilized in 6.25% of modern cardiac surgery, with two‐thirds of cases instituted on the day of surgery or afterwards. The use of tMCS is associated with significantly higher mortality, longer LOS, and higher costs. Among patients undergoing tMCS, earlier utilization is associated with better outcomes.

20 October 2023 in ASAIO Journal
Verified
Journal Article
Closed access
JTJaimin Trivedi
Jaimin Trivedi
SPSiddharth Pahwa
Siddharth Pahwa
DRDavid Godwin Rabkin
David Godwin Rabkin
MGMichele Gallo
Michele Gallo
MGMaya Guglin
Maya Guglin
DADmitry Abramov
Dmitry Abramov
Clinical predictors of posttransplant graft loss since the United Network for Organ Sharing (UNOS) heart allocation system change have not been well characterized. Single organ adult heart transplants from the UNOS database were identified (n = 10,252) and divided into a test cohort (n = 6,869, 67%) and validation cohort (n = 3,383, 33%). A Cox regression analysis was performed on the test cohort to identify recipient and donor risk factors for posttransplant graft loss. Based on the risk factors, a score (max 16) was developed to classify patients in the validation cohort into risk groups of low (≤1), mid (2–3), high (≥4) risk. Recipient factors of advanced age, Black race, recipient blood group O, diabetes, etiology of heart failure, renal dysfunction, elevated bilirubin, redo-transplantation, elevated pulmonary artery pressure, transplant with a durable ventricular assist device, or transplant on extracorporeal membrane oxygenation (ECMO) or ventilator were associated with more posttransplant graft loss. Donor factors of ischemic time and donor age were also associated with outcomes. One year graft survival for the low-, mid-, high-risk groups was 94%, 91%, and 85%, respectively. In conclusion, easily obtainable clinical characteristics at time of heart transplant can predict posttransplant outcomes in the current era.